Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02643303 |
| Title | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Ludwig Institute for Cancer Research |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Research Facility | Atlanta | Georgia | 30322 | United States | Details | |
| Research Facility | Lebanon | New Hampshire | 03756 | United States | Details | |
| Research Facility | Buffalo | New York | 14263 | United States | Details | |
| Research Facility | New York | New York | 10029 | United States | Details | |
| Research Facility | Cleveland | Ohio | 44195 | United States | Details | |
| Research Facility | Toledo | Ohio | 43614 | United States | Details | |
| Research Facility | Charlottesville | Virginia | 22908 | United States | Details |